Catalyst
Slingshot members are tracking this event:
FDA Approves Aralez Pharma's (ARLZ) YOSPRALA for Secondary Prevention of Cardiovascular and Cerebrovascular Events in Patients at Risk of Asprin-Induced Gastric Ulcers
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARLZ |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 15, 2016
Occurred Source:
http://ir.aralez.com/phoenix.zhtml?c=254163&p=irol-newsArticle&ID=2202150
Related Projects
Related Keywords
Yosprala, Cardiovascular Events, Cerebrovascular Events, Asprin-induced, Gastric Ulcers
